CytomX Therapeutics Inc (Nasdaq: CTMX) thiab Regeneron Cov Tshuaj Inc (Nasdaq: ROV LOS) tshaj tawm a kev sib koom tes thiab daim ntawv tso cai pom zoo los tsim cov kev kho mob kheesxaws bispecific conditionally-activated.
Kev sib koom tes yuav siv CytomX's Probody therapeutic platform thiab Regeneron's Veloci-Bi bispecific antibody development platform.
Raws li kev pom zoo, Regeneron thiab CytomX yuav koom tes ntawm cov haujlwm tshawb pom los txheeb xyuas thiab siv tau cov tshuaj tiv thaiv kab mob bispecific.
Regeneron yuav yog lub luag haujlwm rau kev pab nyiaj rau preclinical thiab kho mob kev loj hlob thiab kev ua lag luam.
CytomX yuav tau txais kev them nyiaj ua ntej ntawm $ 30 lab thiab yuav tsim nyog tau txais cov phiaj xwm kev xaiv tsa yav tom ntej thiab kev kho mob, kev kho mob, thiab kev lag luam tseem ceeb txog li $ 2 nphom.
CytomX tseem tsim nyog tau txais cov nyiaj tau txais txiaj ntsig thoob ntiaj teb kev muag khoom.
Thaum Lub Xya Hli, CytomX Therapeutics tau hloov kho nws txoj kev lag luam los ua qhov tseem ceeb ntawm kev nqis peev sab hauv hauv nws cov kev kho mob preclinical thiab cov kav dej thaum ntxov.
Lub tuam txhab txiav 40% ntawm nws cov neeg ua haujlwm. Cov kev hloov pauv yuav tsum txuas ntxiv mus lub tuam txhab nyiaj txiag khiav mus rau 2025.
Nqe Nqis: CTMX shares tau nce 24.43% ntawm $ 1.5057 ntawm daim tshev kawg hnub Thursday.
Saib ntxiv ntawm Benzinga
Tsis txhob nco lub sijhawm ceeb toom ntawm koj cov khoom lag luam - koom Lub Npe Lub Npe Pro dawb! Sim cov cuab yeej uas yuav pab koj nqis peev smarter, sai dua, thiab zoo dua.
© 2022 Benzinga.com. Benzinga tsis muab lus qhia txog peev. Qoob loo.
Tau qhov twg los: https://finance.yahoo.com/news/cytomx-shares-jump-cancer-therapy-161402201.html